Generate Biomedicines Earnings
NASDAQ: GENBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
14.34+0.35 (+2.50%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Thu, Nov 5, 2026
Fiscal period
Sep/2026
EPS estimate
$-0.50
Generate Biomedicines earnings summary
Generate Biomedicines is scheduled to report Sep/2026 earnings on Nov 5, 2026, with analysts expecting EPS of $-0.50. In its most recent report on Aug 6, 2026 (Q2 2026), GENB posted EPS of $-0.52. Revenue for the quarter was $6.3 million.
Summary generated from market data by MetaCap's automated system. Methodology
GENB earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 6, 2026 | — | $-0.52 | — | +9.0% |
| May 7, 2026 | — | $-1.07 | — | +17.1% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.